{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-22-000044","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.379083+00:00","generated_at":"2026-06-21T22:35:19.140473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance","bullets":["Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.","Placed 3 Growth Direct systems in Q3 vs 10 in prior year; validated 4 customer systems.","Net loss $16.3M ($0.38/share) vs $25.0M ($0.71) in Q3 2021; ops expenses rose on strategic review and restructuring.","Reaffirms FY2022 revenue at least $17M; expects at least 2 system placements in Q4.","Cash $150.1M, no debt; strategic review ongoing; restructuring plan targets $8-9M annual savings by Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-22-000044","json":"https://secwatch.observer/filing/0001380106-22-000044.json","markdown":"https://secwatch.observer/filing/0001380106-22-000044.md","text":"https://secwatch.observer/filing/0001380106-22-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/0001380106-22-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010622000044/rpid-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:35:19.140473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}